|
1.
|
Pancreatic Cancer-National Cancer
Institute, U.S National Institutes of Health: Cancer.
Gov.http:www.cancer.gov/cancer-topics/types/pancreaticRetrieved
06-042010.
|
|
2.
|
Maitra A and Hruban RH: Pancreatic cancer.
Annu Rev Pathol. 3:157–188. 2008. View Article : Google Scholar
|
|
3.
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar
|
|
4.
|
Mulcahy MF, Wahl AO and Small W Jr: The
current status of combined radiotherapy and chemotherapy for
locally advanced or resected pancreas cancer. J Natl Compr Canc
Netw. 3:637–642. 2005.PubMed/NCBI
|
|
5.
|
Pino SM, Xiong HQ, McConkey D and
Abbruzzese JL: Novel therapies for pancreatic adenocarcinoma. Curr
Oncol Rep. 6:199–206. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Buffa Filho W, Corsino J, Bolzani da SV,
Furlan M, Pereira AM and Franca SC: Quantitative determination for
cytotoxic Friedo-nor-oleanane derivatives from five morphological
types of Maytenus ilicifolia (Celastraceae) by reverse-phase
high-performance liquid chromatography. Phytochem Anal. 13:75–78.
2002.PubMed/NCBI
|
|
7.
|
Chang FR, Hayashi K, Chen IH, et al:
Antitumor agents. 228. Five new agarofurans, Reissantins A-E, and
cytotoxic principles from Reissantia buchananii. J Nat Prod.
66:1416–1420. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Sassa H, Kogure K, Takaishi Y and Terada
H: Structural basis of potent antiperoxidation activity of the
triterpene celastrol in mitochondria: effect of negative membrane
surface charge on lipid peroxidation. Free Radic Biol Med.
17:201–207. 1994. View Article : Google Scholar
|
|
9.
|
Dirsch VM, Kiemer AK, Wagner H and Vollmar
AM: The triterpenoid quinonemethide pristimerin inhibits induction
of inducible nitric oxide synthase in murine macrophages. Eur J
Pharmacol. 336:211–217. 1997. View Article : Google Scholar
|
|
10.
|
Figueiredo JN, Raz B and Sequin U: Novel
quinone methides from Salacia kraussii with in vitro
antimalarial activity. J Nat Prod. 61:718–723. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Brinker AM, Ma J, Lipsky PE and Raskin I:
Medicinal chemistry and pharmacology of genus Tripterygium
(Celastraceae). Phytochemistry. 68:732–766. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Costa PM, Ferreira PM, Bolzani Vda S, et
al: Antiproliferative activity of pristimerin isolated from
Maytenus ilicifolia (Celastraceae) in human HL-60 cells.
Toxicol In Vitro. 22:854–863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Yang H, Landis-Piwowar KR, Lu D, et al:
Pristimerin induces apoptosis by targeting the proteasome in
prostate cancer cells. J Cell Biochem. 103:234–244. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Yan YY, Bai JP, Xie Y, Yu JZ and Ma CG:
The triterpenoid pristimerin induces U87 glioma cell apoptosis
through reactive oxygen species-mediated mitochondrial dysfunction.
Oncol Lett. 5:242–248. 2013.
|
|
15.
|
Lee JS, Yoon IS, Lee MS, et al: Anticancer
activity of pristimerin in epidermal growth factor receptor
2-positive SKBR3 human breast cancer cells. Biol Pharm Bull.
36:316–325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR
and Wu YC: Pristimerin induces caspase-dependent apoptosis in
MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer
Ther. 4:1277–1285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Lu Z, Jin Y, Chen C, Li J, Cao Q and Pan
J: Pristimerin induces apoptosis in imatinib-resistant chronic
myelogenous leukemia cells harboring T315I mutation by blocking
NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer. 9:1122010.
View Article : Google Scholar
|
|
18.
|
Byun JY, Kim MJ, Eum DY, et al: Reactive
oxygen species-dependent activation of Bax and poly(ADP-ribose)
polymerase-1 is required for mitochondrial cell death induced by
triterpenoid pristimerin in human cervical cancer cells. Mol
Pharmacol. 76:734–744. 2009. View Article : Google Scholar
|
|
19.
|
Mu XM, Shi W, Sun LX, et al: Pristimerin
inhibits breast cancer cell migration by up-regulating regulator of
G protein signaling 4 expression. Asian Pac J Cancer Prev.
13:1097–1104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Mu X, Shi W, Sun L, Li H, Jiang Z and
Zhang L: Pristimerin, a triterpenoid, inhibits tumor angiogenesis
by targeting VEGFR2 activation. Molecules. 17:6854–6868. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Wang Y, Zhou Y, Zhou H, et al: Pristimerin
causes G1 arrest, induces apoptosis, and enhances the
chemosensitivity to gemcitabine in pancreatic cancer cells. PLoS
One. 7:e438262012. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Sun XM, MacFarlane M, Zhuang J, Wolf BB,
Green DR and Cohen GM: Distinct caspase cascades are initiated in
receptor-mediated and chemical-induced apoptosis. J Biol Chem.
274:5053–5060. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ashkenazi A and Dixit VM: Death receptors:
signaling and modulation. Science. 281:1305–1308. 1998. View Article : Google Scholar
|
|
24.
|
Li H, Zhu H, Xu CJ and Yuan J: Cleavage of
BID by caspase 8 mediates the mitochondrial damage in the Fas
pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Luo X, Budihardjo I, Zou H, Slaughter C
and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c
release from mitochondria in response to activation of cell surface
death receptors. Cell. 94:481–490. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Datta SR, Dudek H, Tao X, et al: Akt
phosphorylation of BAD couples survival signals to the
cell-intrinsic death machinery. Cell. 91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Brunet A, Bonni A, Zigmond MJ, et al: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Karin M, Cao Y, Greten FR and Li ZW:
NF-kappaB in cancer: from innocent bystander to major culprit. Nat
Rev Cancer. 2:301–310. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Mayo MW and Baldwin AS: The transcription
factor NF-kappaB: control of oncogenesis and cancer therapy
resistance. Biochim Biophys Acta. 1470:M55–M62. 2000.PubMed/NCBI
|
|
31.
|
Liu L, Li F, Cardelli JA, Martin KA,
Blenis J and Huang S: Rapamycin inhibits cell motility by
suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene.
25:7029–7040. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Bjornsti MA and Houghton PJ: The TOR
pathway: a target for cancer therapy. Nat Rev Cancer. 4:335–348.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Green DR and Reed JC: Mitochondria and
apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar
|
|
34.
|
Deveraux QL and Reed JC: IAP family
proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Breitschopf K, Haendeler J, Malchow P,
Zeiher AM and Dimmeler S: Posttranslational modification of Bcl-2
facilitates its proteasome-dependent degradation: molecular
characterization of the involved signaling pathway. Mol Cell Biol.
20:1886–1896. 2000. View Article : Google Scholar
|
